BioMarin Pharmaceutical

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. 

Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany.

1997: BioMarin (BMRN) is based in San Rafael, California, and was founded. When BioMarin first opened its doors+, treatment of rare diseases was as rare as the conditions themselves.

1999: BioMarin was listed on the NASDAQ stock exchange.

2009: BioMarin acquired Huxley Pharmaceuticals Inc.

To bring new treatments to market that will make a big impact on small patient populations. These patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide.

At BioMarin, we view ourselves as a team of pioneers willing to take risks in the quest to find new solutions to address the biggest challenges in rare diseases, and motivated by the desire to help improve the lives of patients with unmet medical needs.